Short answer
Candel Therapeutics, Inc. (CADL) filed an 8-K current report with the SEC on September 10, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Board expanded from 10 to 11 directors; Martine Zimmermann appointed independent Class III director through 2027 annual meeting.
Candel Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded from 10 to 11 directors; Martine Zimmermann appointed independent Class III director through 2027 annual meeting
- Regulatory expertise spanning FDA, EMA and Japanese authorities strengthens oversight of drug-development and approval strategy
- Equity compensation: option for 64,000 shares, vesting monthly over three years
- Annual board retainer: $40,000, paid quarterly and prorated for service
- Appointment adds a senior biopharmaceutical regulator with experience at Inventiva, Ipsen and Alexion
Item 7.01 · Regulation FD Disclosure
- Martine Zimmermann, PharmD appointed to Candel Therapeutics’ Board of Directors
- Board addition may strengthen pharmaceutical development and commercialization expertise
- Press release furnished as Exhibit 99.1 for appointment details
Item EX-99.1 · Exhibit EX-99.1
- Martine Zimmermann appointed to Candel’s Board effective September 8, 2026
- More than 30 years of regulatory and quality experience strengthens oversight ahead of planned BLA submission
- BLA submission for aglatimagene besadenovec targeted for fourth quarter 2026
- Board addition supports potential commercial readiness but does not change approval risk
- Aglatimagene remains investigational and unapproved by the FDA or other regulators
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Candel Therapeutics, Inc. 8-K filings
Get the next CADL 8-K as it lands
Follow CADL for push alerts, or ask the research agent what this filing means.